AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$REGN

Guggenheim raises Regeneron stock price target to $1,100 on strong Q3 results

Guggenheim raised its price target on Regeneron (NASDAQ:REGN) to $1,100 from $1,030, citing strong Q3 2026 results. Revenue was $5.116B, beating estimates, with EPS at $20.07. Sanofi collaboration revenue hit a record $2.724B. The stock has risen 14.88% in a week, nearing its 52-week high.

Original reporting
investing.com
Published Nov 2, 2026, 9:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The earnings beat and target raise are likely to lift Regeneron and may spill over to peers.

02

Market read

Regeneron's strong quarter and upgraded target provide a fresh trading catalyst for the stock and its sector.

03

Timing

pre‑market today

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Regeneron disclosed Q3 earnings that exceeded consensus, driven by Sanofi collaboration and strong product sales.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron reported Q3 2026 revenue of $5.12B and non‑GAAP EPS of $20.07, beating estimates, prompting Guggenheim to raise its price target to $1,100.

Expected impact

likely upward pressure as investors price in the earnings beat and higher target

Evidence & confidence

Strong revenue growth, record collaboration revenue, and a significant price‑target increase provide a clear catalyst for buying pressure.

Market effects

Sector

Biotech sector may see broader rally on Regeneron's strong results and Sanofi partnership.

Regional

U.S. biotech stocks could benefit from the earnings beat.

Global

Highlights strength of US‑based biotech firms in a competitive global landscape.

Key entities

  • company
    Regeneron Pharmaceuticals

    Biotech firm reporting Q3 2026 results.

  • analyst
    Guggenheim

    Raised price target on Regeneron to $1,100.

Read at source← All news

StoryRegeneron posts blockbuster Q3 results, prompting analysts to lift price targets

Also covered by

3 outlets

Related articles

NOV 2
HighAI 8/10

Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals' stock rose 4.0% to a 52-week high of $972.06 after reporting Q3 2026 earnings of $20.07 per share, up 70% Y/Y, and revenue of $5.116B, up 36% Y/Y. Multiple analysts raised price targets, with BofA Securities at $1,030 and Canaccord Genuity at $1,175. Positive Phase 3 trial data for Libtayo also supported the stock.

investing.com2 min
NOV 2
$REGNMedAI 9/10

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

ibtimes.com.au5 min
NOV 2
$AZNMed

Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

finance.yahoo.com7 min